Canada Clears SQI Test for Celiac Disease | GenomeWeb

NEW YORK (GenomeWeb News) – Health Canada has issued a license to SQI Diagnostics allowing the company to market its multiplexed Ig_plex Celiac DGP Panel, the Toronto-based firm said today.

The panel is intended for use in clinical laboratories to help diagnose celiac disease and provides semi-quantitative determination of the IgG and IgA immunoglobulin classes of deamidated gliadin peptide and anti-tissue transglutaminase antibodies in a single test that requires only one human sample, SQI said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.